Numeno.ai

Numeno.ai is focused on enhancing patient outcomes and reducing human suffering through the use of artificial intelligence in the pharmaceutical and drug development sectors. Founded on August 1, 2024, the company operates a B2B model, providing software solutions that improve the efficiency and effectiveness of clinical trials and drug development processes.

The core offering is the CURE platform, which integrates and analyzes real-world data and clinical trial data from Phase I to Phase IV. This platform provides insights that support data-driven decision-making, patient stratification, and target discovery. By maximizing the value of clinical data, CURE helps pharmaceutical companies improve trial significance and differentiate their drugs effectively.

Numeno.ai's team includes experts in AI, pharmaceutical research, clinical trials, and biomarker strategy development. Their diverse expertise allows the company to tackle complex challenges in drug development and clinical research, ultimately supporting pharmaceutical companies and researchers in improving drug development outcomes and patient care.